Carbonic anhydrase inhibitors protect against tau protein build-up
Nov 1, 2024 · Scientists at the UK Dementia Research Institute, University of Cambridge, have identified a drug commonly used to treat glaucoma can protect against tau protein build-up in the brain in genetically engineered zebrafish and mice. They screened over 1,437 clinically-approved drug compounds and found that carbonic anhydrase inhibitors, of which the glaucoma drug methazolamide is one, remove tau ...
New insights into adhesion GPCRs spark drug design potential
Dec 27, 2024 · Researchers at the University of Chicago have uncovered the full structure of adhesion GPCRs, revealing new activation mechanisms.
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade. The current shift focuses on enhancing their efficacy by addressing the crucial need for robust T cell responses, an apparent bottleneck for broader impact ...
Drug Target Review: Leading Research & Insights in Drug Discovery
Featured FDA’s Project Optimus: A new era in oncology drug dosing Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
New AI model may enable more targeted prostate cancer treatment
Oct 30, 2024 · Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions.
The art and science of drug formulation - Drug Target Review
Aug 9, 2024 · Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring the future potential of AI, 3D ...
Exploring the potential of ADCs beyond oncology - Drug Target …
Aug 6, 2024 · What are the main therapeutic areas beyond oncology where ADCs show potential? A number of areas represent significant opportunities for Antibody Drug Conjugates (ADCs) beyond oncology, leveraging their ability to deliver therapeutic agents specifically to diseased cells or tissues while minimising off-target effects. The development of ADCs in these areas is ongoing, with several preclinical ...
NKTR-255 shows positive results in lymphoma therapy
Dec 16, 2024 · Nektar Therapeutics presented promising results at the 66th Annual ASH Meeting, showing that NKTR-255, an investigational IL-15 agonist, significantly boosts the complete response rate (CRR) in patients with relapsed/refractory large B-cell lymphoma (LBCL) after CD19-directed CAR-T therapy.
Novel nasal spray effectively prevents influenza infection
Sep 25, 2024 · The nasal spray reduced influenza virus levels by >99.99 percent, which could safeguard public health if validated in humans.
Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
Jun 18, 2024 · At this year’s ASGCT conference, Tessera shared progress on its RNA Gene Writers™, including promising data in preclinical models of AATD.